Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib

Intern Med. 2022 Aug 15;61(16):2503-2508. doi: 10.2169/internalmedicine.8760-21. Epub 2022 Feb 1.

Abstract

A 74-year-old woman was diagnosed with Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in X-18. Fludarabine plus rituximab (FR) was started, and she showed remission. In July X-7, the serum creatinine (Cr) level increased to 1.67 mg/dL, and bendamustine plus rituximab (BR) was started. By November X-7, the Cr level had increased to 8.41 mg/dL, so she was started on hemodialysis (HD). In September X-1, she developed nephrotic syndrome. She was started on tirabrutinib at 480 mg. In July X, her nephrotic syndrome had improved, and a complete response (CR) was achieved. This is the first case of the administration of tirabrutinib in a patient undergoing HD.

Keywords: Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL); chronic renal failure; hemodialysis; nephrotic syndrome; tirabrutinib.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Humans
  • Imidazoles
  • Lymphoma* / complications
  • Nephrotic Syndrome* / complications
  • Nephrotic Syndrome* / drug therapy
  • Pyrimidines
  • Renal Dialysis
  • Rituximab / therapeutic use
  • Waldenstrom Macroglobulinemia* / complications
  • Waldenstrom Macroglobulinemia* / diagnosis
  • Waldenstrom Macroglobulinemia* / drug therapy

Substances

  • Imidazoles
  • Pyrimidines
  • Rituximab
  • tirabrutinib